📝 CereCura raises $1.4M CAD

In partnership with

News of the Day

CereCura Nanotherapeutics has raised $1.4 million CAD in seed funding to advance a new class of treatments for brain disorders built on the same lipid nanoparticle RNA (LNP-RNA) technology that powered the Moderna and Pfizer COVID-19 vaccines. The UBC spinout, founded by LNP pioneer Pieter Cullis and neuroscientist Louis-Philippe Bernier, has already shown it can deliver multiple therapeutic proteins across the blood-brain barrier in rodents — a breakthrough in tackling diseases like Alzheimer’s, Parkinson’s, and neuronopathic Gaucher disease, where drug delivery has long been the critical bottleneck. Backed by WUTIF Capital, eFund, UBC Venture Funds, and others, and buoyed by more than $4 million in government grants, CereCura is now working to validate its “**Trojan horse**” LNP approach in larger animals, betting that enabling the brain to manufacture its own therapeutic proteins will redefine how neurodegenerative diseases are treated.

If you have tweets you want to submit to be featured here (from you or someone you like), reply to this email with a link!

Chart of the Day